Osteoporosis Pharmacotherapy

Pharmacotherapy for osteoporosis aims to reduce the risk of fragility fracture by strengthening bone. The available drug classes act in two broad ways: antiresorptive agents slow the breakdown of bone, while anabolic agents stimulate new bone formation. Their mechanisms map directly onto the biology of bone remodeling and the signaling pathways that regulate it.

Definition

Osteoporosis pharmacotherapy is the use of antiresorptive or anabolic medications to reduce bone fragility and the risk of fracture, acting on the cellular pathways that govern bone resorption and formation.

Scope

This entry surveys the principal drug classes used in osteoporosis and the mechanisms by which they act, with reference to the landmark trials that demonstrated fracture reduction. It is reference-educational and deliberately non-prescriptive: it explains how the therapies work and what the evidence shows, and it does not recommend, sequence, dose, or compare treatments for any individual.

Core questions

• What distinguishes antiresorptive from anabolic therapy?
• How do bisphosphonates and denosumab reduce bone resorption?
• How do teriparatide and romosozumab stimulate bone formation?
• What outcomes do osteoporosis trials measure?
• How does drug mechanism relate to bone remodeling biology?

Key concepts

• Antiresorptive therapy
• Anabolic (bone-forming) therapy
• Bisphosphonates
• RANKL inhibition (denosumab)
• PTH-pathway anabolics (teriparatide)
• Sclerostin inhibition (romosozumab)
• Fracture-endpoint trials
• Bone mineral density as a surrogate

Mechanisms

Antiresorptive drugs lower bone turnover by suppressing osteoclasts. Bisphosphonates bind to bone mineral and impair osteoclast function and survival; once-yearly zoledronic acid reduced vertebral and hip fractures in a randomized trial (Black et al., 2007). Denosumab is a monoclonal antibody that inhibits RANKL, blocking osteoclast formation through the same axis described in bone biology, and reduced fractures in a large trial (Cummings et al., 2009). Anabolic drugs instead stimulate bone formation: teriparatide, a fragment of parathyroid hormone, increases osteoblast activity and reduced vertebral and nonvertebral fractures (Neer et al., 2001), while romosozumab, an antibody against sclerostin, transiently increases formation and decreases resorption by relieving WNT-pathway inhibition (Cosman et al., 2016). The choice among these mechanisms reflects how each acts on the remodeling cycle.

Clinical relevance

These therapies are the means by which fracture risk can be lowered in people with osteoporosis, and understanding their mechanisms clarifies why they are grouped as antiresorptive or anabolic. This entry presents that mechanistic and evidentiary background for reference only; it is not clinical guidance and does not address who should receive a drug, in what order, or at what dose.

Evidence & guidelines

The fracture-reduction evidence for these agents comes from large randomized controlled trials (Black et al., 2007; Cummings et al., 2009; Neer et al., 2001; Cosman et al., 2016), and authoritative clinician guidance synthesizes this evidence into recommendations (Cosman et al., 2014). The present entry summarizes the evidence base rather than reproducing specific recommendations.

History

Bisphosphonates became the foundation of osteoporosis therapy in the 1990s and 2000s. The elucidation of the RANKL and WNT/sclerostin pathways then enabled targeted biologics — denosumab against RANKL and romosozumab against sclerostin — while parathyroid-hormone analogues introduced an anabolic strategy, broadening treatment from purely slowing resorption to actively building bone.

Key figures

• Dennis M. Black
• Steven R. Cummings
• Robert M. Neer
• Felicia Cosman

Seminal works

• black-2007
• cummings-2009
• neer-2001
• cosman-2016-frame

Frequently asked questions

What is the difference between antiresorptive and anabolic osteoporosis drugs?

Antiresorptive drugs (such as bisphosphonates and denosumab) slow the breakdown of bone by suppressing osteoclasts, whereas anabolic drugs (such as teriparatide and romosozumab) stimulate osteoblasts to build new bone.

How do these drugs relate to bone remodeling biology?

They act on the same pathways that regulate remodeling: denosumab targets RANKL to limit osteoclasts, romosozumab targets sclerostin to release the WNT brake on formation, and bisphosphonates impair osteoclast function directly.